Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...
The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...
RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results